Seagen reports progression free survival data from Adcetris combination study

Seagen announced that the clinical research cooperative German Hodgkin Study Group, or GHSG, presented results showing that a phase 3 trial of Adcetris in combination with chemotherapy – a regimen called BrECADD met its co-primary endpoints of non-inferior efficacy and superior tolerability versus a highly efficacious yet chemotherapy-intense treatment regimen of escalated BEACOPP, which is an international standard of care in the frontline advanced classical Hodgkin lymphoma, or cHL, setting and commonly used in Europe. Both study arms used PET scans to guide treatment decisions. The data results of the HD21 study were presented in a late-breaking session at the 17th International Conference on Malignant Lymphoma, or ICML. in Lugano, Switzerland on June 17. An interim analysis at 40 months showed an unprecedented 94.9% three-year progression-free survival for patients treated with the ADCETRIS combination of BrECADD versus 92.3% for eBEACOPP. Also, 12-month post-treatment safety data were consistent with previously presented HD21 data results at the American Society of Hematology 2022 Annual Meeting. ADCETRIS + AVD chemotherapy is a U.S. standard of care in advanced-stage cHL and is the only targeted therapy inclusive regimen that has a proven statistically significant overall survival benefit at six-years of follow-up compared to ABVD, reducing risk of death by 41% for these patients.